Core Insights - The company, Yingke Medical, reported a significant increase in both revenue and net profit for the year 2024, with total revenue reaching 9.523 billion yuan, a year-on-year increase of 37.65%, and net profit of 1.465 billion yuan, up 282.63% [1][4] - The fourth quarter of 2024 showed particularly strong performance, with revenue of 2.425 billion yuan, a 29.21% increase year-on-year, and net profit soaring to 778 million yuan, reflecting a staggering increase of 1391.98% [1] - The company's profitability improved markedly, with gross margin increasing by 72.56% to 23.64% and net margin rising by 179.26% to 15.66% [1][4] Financial Performance - Total revenue for 2024 was 9.523 billion yuan, compared to 6.919 billion yuan in 2023, marking a 37.65% increase [4] - Net profit for 2024 was 1.465 billion yuan, up from 383 million yuan in 2023, representing a 282.63% increase [4] - The company reported a significant increase in non-recurring net profit, which reached 1.167 billion yuan, a year-on-year increase of 1239.10% [4] Cost and Efficiency - Total expenses related to sales, management, and finance amounted to 370 million yuan, which is 3.88% of revenue, down 37.76% year-on-year [4] - The company’s cash flow from operating activities increased significantly, with a year-on-year growth of 114.78% [8] Market Expectations - Analysts had previously estimated the company's net profit for 2024 to be around 1.257 billion yuan, indicating that the actual results exceeded expectations [2] - Forecasts for 2025 suggest a net profit of approximately 1.516 billion yuan, with an average earnings per share of 2.34 yuan [5] Shareholder Information - The largest fund holding Yingke Medical shares is the GF聚瑞混合A, which holds 3.3198 million shares, reflecting an increase in position [6] - The fund's current scale is 1.516 billion yuan, with a recent net value of 3.5526, showing a decline of 0.93% from the previous trading day but an increase of 26.89% over the past year [6]

Group 1 - Shenjian Co., Ltd. reported a net profit of 33.65 million yuan for 2024, a year-on-year increase of 32.29%, with a proposed cash dividend of 0.5 yuan per 10 shares [1] - Jingce Electronics experienced a net loss of 97.60 million yuan in 2024, transitioning from profit to loss, despite a revenue increase of 5.59% to 2.565 billion yuan [1] - Jingwei Co., Ltd. reported a net profit of 35.54 million yuan for 2024, a decrease of 36.76%, with a proposed cash dividend of 1.00 yuan per 10 shares [1][2] Group 2 - Minsheng Health achieved a net profit of 91.83 million yuan in 2024, a year-on-year increase of 7.24%, with a proposed cash dividend of 1.00 yuan per 10 shares [2] - Zhongshe Co., Ltd. reported a net profit of 10.16 million yuan for 2024, a decline of 76.24%, with a proposed cash dividend of 0.2 yuan per 10 shares [3] - Keyuan Smart reported a net profit of 252 million yuan for 2024, a year-on-year increase of 56.64%, with a proposed cash dividend of 0.4 yuan per 10 shares [4] Group 3 - Beilu Pharmaceutical reported a net profit of 14.54 million yuan for Q1 2025, a year-on-year increase of 26.13%, with revenue of 283 million yuan [5] - Wangsu Technology achieved a net profit of 192 million yuan for Q1 2025, a year-on-year increase of 38.54%, with revenue of 1.235 billion yuan [6] - Keyuan Pharmaceutical reported a net profit of 23.08 million yuan for Q1 2025, a year-on-year increase of 7.25%, despite a revenue decline of 23.98% [7] Group 4 - Guangting Information reported a net profit of 24.03 million yuan for Q1 2025, turning from loss to profit, with revenue of 134 million yuan [9] - Zhaori Technology reported a net loss of 1.23 million yuan for Q1 2025, with revenue of 35.23 million yuan [11] - Huakai Yibai reported a net loss of 15.09 million yuan for Q1 2025, despite revenue growth of 35.08% to 2.292 billion yuan [13] Group 5 - Xinhongye reported a net profit of 34.43 million yuan for Q1 2025, a year-on-year increase of 20.43%, with revenue of 755 million yuan [15] - Huning Co., Ltd. reported a net profit of 3.61 million yuan for Q1 2025, a year-on-year decrease of 45.68%, with revenue of 64.51 million yuan [16] - Camel Co., Ltd. reported a net profit of 237 million yuan for Q1 2025, a year-on-year increase of 51.89%, with revenue of 4.136 billion yuan [17] Group 6 - Hengtong Co., Ltd. reported a net profit of 42.55 million yuan for Q1 2025, a year-on-year increase of 51.62%, with revenue of 313 million yuan [19] - Changqing Technology reported a net profit of 35.38 million yuan for Q1 2025, a year-on-year decrease of 23.80%, with revenue of 246 million yuan [21] - Libaba Co., Ltd. reported a net profit of 34.72 million yuan for Q1 2025, a year-on-year increase of 9.91%, with revenue of 419 million yuan [22] Group 7 - Shouxiangu reported a net profit of 58.37 million yuan for Q1 2025, a year-on-year decrease of 24.32%, with revenue of 171 million yuan [24] - Bojun Technology announced a stock issuance application accepted by the Shenzhen Stock Exchange [24] - Dayou Energy announced the full resumption of production at its Gengcun coal mine, with an annual production capacity of 3.6 million tons [25] Group 8 - Deyang Co., Ltd. successfully acquired land use rights for industrial land in Ningbo for 45.80 million yuan [27] - Tianyu Pharmaceutical's subsidiary received a drug registration certificate for an injectable product [29] - Xingwang Yuda signed a strategic cooperation agreement with the Jilin Province Bionic Robot Innovation Center [30] Group 9 - Lifang Pharmaceutical received approval for clinical trials of a new drug [32] - Zai Sheng Technology reported a net profit of 33.56 million yuan for Q1 2025, a year-on-year increase of 3.69%, with revenue of 324 million yuan [34] - Jinxin Technology reported a net profit of 319,920 yuan for Q1 2025, turning from loss to profit, with revenue of 563 million yuan [36] Group 10 - Huayin Electric reported a net profit of 75.67 million yuan for Q1 2025, a year-on-year increase of 894.61%, with revenue of 2.307 billion yuan [37] - Xinghua Co., Ltd. reported a net loss of 95.51 million yuan for Q1 2025, with revenue of 840 million yuan [38] - Heren Technology reported a net loss of 384,410 yuan for Q1 2025, with revenue of 78.40 million yuan [40] Group 11 - Fenda Technology reported a net profit of 40.45 million yuan for Q1 2025, a year-on-year increase of 84.07%, with revenue of 760 million yuan [41] - Tongda Co., Ltd. reported a net profit of 25.49 million yuan for 2024, a year-on-year decrease of 69.15%, with revenue of 6.201 billion yuan [43] - Zhonghe Holdings reported a net profit of 283 million yuan for 2024, a year-on-year decrease of 54.69%, with a proposed cash dividend of 0.3 yuan per 10 shares [44] Group 12 - Jiantou Energy reported a net profit of 531 million yuan for 2024, a year-on-year increase of 181.59%, with a proposed cash dividend of 1.3 yuan per 10 shares [44] - Guanghua Technology reported a net loss of 205 million yuan for 2024, with revenue of 2.589 billion yuan [45] - Huajin Technology reported a net profit of 29.26 billion yuan for 2024, a year-on-year increase of 8.1%, with a proposed cash dividend of 9 yuan per 10 shares [46] Group 13 - Yingke Medical reported a net profit of 1.465 billion yuan for 2024, a year-on-year increase of 282.63%, with a proposed cash dividend of 1.00 yuan per 10 shares [46] - Solar Energy reported a net profit of 1.225 billion yuan for 2024, a year-on-year decrease of 22.38%, with a proposed cash dividend of 0.56 yuan per 10 shares [46] - Dongfang Electric reported a net profit of 318 million yuan for 2024, a year-on-year decrease of 50.62%, with a proposed cash dividend of 0.32 yuan per 10 shares [47] Group 14 - Tianneng Heavy Industry reported a net loss of 262 million yuan for 2024, with revenue of 3.273 billion yuan [48] - Gangyan High-tech reported a net profit of 249 million yuan for 2024, a year-on-year decrease of 22.08%, with a proposed cash dividend of 1.00 yuan per 10 shares [48] - Shihua Machinery reported a net profit of 96.88 million yuan for 2024, a year-on-year increase of 5.35%, with revenue of 8.037 billion yuan [49] Group 15 - Gongtong Pharmaceutical reported a net loss of 27.59 million yuan for 2024, with revenue of 537 million yuan [51] - Zhongjing Electronics reported a net loss of 87.43 million yuan for 2024, with revenue of 2.932 billion yuan [53] - Yudai Development reported a net loss of 114 million yuan for 2024, with revenue of 388 million yuan [55] Group 16 - Zhenhua Technology reported a net profit of 970 million yuan for 2024, a year-on-year decrease of 63.83%, with a proposed cash dividend of 1.8 yuan per 10 shares [56] - Jierong Technology reported a net loss of 298 million yuan for 2024, with revenue of 1.357 billion yuan [58] - Changgao Electric New reported a net profit of 252 million yuan for 2024, a year-on-year increase of 45.66%, with a proposed cash dividend of 0.8 yuan per 10 shares [60] Group 17 - Shibao Detection announced a plan to acquire 81% of Zhonghuan Lianshu for 52.65 million yuan [61] - Jiangsu Boyun announced a plan to reduce its shareholding by up to 3% [62] - Jingfeng Mingyuan announced a plan to acquire 100% of Yichong Technology for 3.283 billion yuan [63]

Core Insights - In 2024, the company reported a revenue of 9.523 billion yuan, representing a year-on-year growth of 37.65% [1] - The net profit attributable to shareholders reached 1.465 billion yuan, a significant increase of 282.63% year-on-year [1] - The net profit excluding non-recurring gains and losses was 1.167 billion yuan, showing a remarkable growth of 1239.1% [1] - The company proposed a cash dividend of 1 yuan per 10 shares for the 2024 fiscal year [1] Industry Overview - The global disposable glove market is gradually returning to a rational development track after experiencing extreme supply-demand imbalances in recent years [1] - From 2020 to 2021, the disposable medical glove industry saw rapid capacity expansion, followed by a stabilization in demand, leading to a temporary oversupply situation [1] - By the second half of 2023, the industry began to clear excess inventory, resulting in improved capacity utilization and a balanced supply-demand relationship in 2024 [1] Company Production Capacity - The company’s annual production capacity for disposable gloves is 87 billion units, with 56 billion units for nitrile gloves and 31 billion units for PVC gloves [2] - The company is also advancing its overseas project development [2] Market Demand - Mature markets such as the US, Europe, and Japan remain the primary demand sources, while domestic and developing markets are expected to be significant growth areas for the future [2] Rehabilitation and Care Business - The rehabilitation and care segment achieved a revenue of 458 million yuan in 2024, reflecting a year-on-year growth of 15.64% [2] - The company is focusing on developing high-end smart products in the wheelchair category and plans to enhance R&D investment in various assistive devices [2] R&D Investment - The company’s total R&D expenditure was 398 million yuan, with an R&D expense ratio of 4.18% [2] - As of the end of the reporting period, the company and its subsidiaries held a total of 282 patents [2]

对于社保基金，本期较上一季度持股减少的社保基金共计1个，即全国社保基金一零八组合，，持股减 少占比达0.13%。本期新披露持有英科医疗的社保基金共计1个，即全国社保基金四一一组合。 外资态度来看，本期较上一季度持股减少的外资基金共计1个，即香港中央结算有限公司，持股减少占 比达1.75%。 2025年4月24日，英科医疗(300677.SZ)发布2024年年度报告。截至2025年4月23日，共有359个机构投资 者披露持有英科医疗A股股份，合计持股量达1.07亿股，占英科医疗总股本的16.61%。其中，前十大机 构投资者包括中国银行股份有限公司-华宝中证医疗交易型开放式指数证券投资基金、香港中央结算有 限公司、中国工商银行股份有限公司-易方达创业板交易型开放式指数证券投资基金、中国农业银行股 份有限公司-中证500交易型开放式指数证券投资基金、中国工商银行股份有限公司-广发聚瑞混合型证 券投资基金、全国社保基金一零八组合、中国工商银行股份有限公司-广发盛兴混合型证券投资基金、 泰康人寿保险有限责任公司-投连-创新动力、全国社保基金四一一组合、南方兴润价值一年持有混合 A，前十大机构投资者合计持股比例达9.71 ...

Core Viewpoint - In its 2024 financial report, Yingke Medical (300677) announced a revenue of 9.523 billion yuan and a net profit of 1.465 billion yuan, marking a recovery with year-on-year growth rates of 37.65% and 282.63% respectively. However, the company faces significant long-term challenges due to its heavy reliance on nitrile gloves, high dependence on overseas revenue, and limitations in its "trade + manufacturing" strategy [1][2][5]. Financial Performance - The company's net profit for 2024 reached 1.465 billion yuan, a dramatic increase of 282.63% compared to 3.83 billion yuan in 2023 [2]. - The total revenue for 2024 was 9.523 billion yuan, reflecting a year-on-year growth of 37.65% from 6.919 billion yuan in 2023 [2]. - The gross profit margin improved due to a rise in the average selling price of nitrile gloves, which contributed over 90% of the company's revenue [2][3]. Product Structure and Market Dependency - Nitrile gloves accounted for 90.31% of the revenue, highlighting a structural imbalance in the product portfolio [2][6]. - The company experienced a significant drop in net profit from 6.29 billion yuan in 2022 to 3.83 billion yuan in 2023, a decline of 39.12%, due to industry destocking [2][3]. Competitive Landscape and Strategic Challenges - The company faces intensified competition as production capacity shifts to countries like Malaysia and new domestic capacities are released [3]. - Despite increasing total production capacity to 87 billion gloves in 2024, overseas subsidiaries reported losses, indicating challenges in global capacity coordination [3][5]. Revenue Composition and Geopolitical Risks - 84.69% of the company's revenue comes from overseas markets, with significant exposure to U.S. tariffs that are set to increase to 50% in 2025 and 100% in 2026 [5][6]. - The reliance on currency fluctuations for profit growth is precarious, as the company benefited from a 42.49% reduction in financial expenses and over 300 million yuan in exchange gains [5]. Leadership and Strategic Direction - Liu Fangyi, the founder, is attempting to navigate the company through a crisis with a new management team, aiming to explore the home care market [7]. - The "5G Global Strategy" faces challenges, including slow progress in the Vietnam factory and local competition in Malaysia, while domestic market channel development lags [7].

英科医疗科技股份有限公司 度非经营性资金占用及其他关联资金往来情况汇总表 单位:人民币万元 | 非经营性资金占用 | 资金占 用方名 | 占用方与上市 公司的关联关 算的会计科 | 上市公司核 | 2024 年期初占 | 2024年度占用累计 发生金额(不含利 | 2024年度偿还累 | 2024年度期末 占用形成 | | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 称 | 系 | 目 | 用资金余额 | 息) | 计发生金额 | 占用资金余额 | 原因 | | | 控股股东、实际控 | | | | | 不适用 | | | | | | 制人及其附属企业 | | | | | | | | | | | 小 计 | | | | | 不适用 | | | | | | 前控股股东、实际 | | | | | | | | | | | 控制人及其附属企 | | | | | 不适用 | | | | | | 12 | | | | | | | | | | | 小 计 | | | | | 不适用 | | | | | | 其他关联方及其附 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-046 英科医疗科技股份有限公司 关于公司及子公司向银行申请授信额度 及担保事项的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第四届董事会第二次（定期）会议、第四届监事会第二 次（定期）会议，审议通过了《关于公司及子公司向银行申请授信额 度及担保事项的议案》，该议案尚需提交公司 2024 年度股东大会审 议。 现将相关情况公告如下： 一、申请授信及相关担保情况概述 为满足公司及子公司的生产经营需要，公司及子公司拟向银行等 金融机构申请综合授信的额度以及金融衍生品交易风险限额的总额 （"授信额度"）不超过 360 亿元人民币，对其担保总额不超过 360 亿元人民币。综合授信用于办理流动资金贷款、项目资金贷款、银行 承兑汇票、信用证、打包贷款、应收账款保理、进出口押汇、商业票 据贴现、银行保函、融资租赁、金融衍生品等各种贷款及贸易融资业 务。 上述授信额度并不代表实际使用的融资额度，实际使用额度以向 银行实际取得的贷 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-049 英科医疗科技股份有限公司 关于公司 2025 年度日常性关联交易预计暨 2024 年 度日常性关联交易确认的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 鉴于市场不断变化，公司生产经营将根据市场变化情况进行适时 调整，因此在年初对全年关联交易总额进行的预测不排除实际执行中 有增减变化的可能。 公司日常关联交易是在平等、互利的基础上进行的，没有损害公 司及股东利益，对公司的财务状况、经营成果不会产生重大影响，也 不会影响公司的独立性，不存在对关联方较大依赖的情况。同时根据 《深圳证券交易所创业板股票上市规则》《英科医疗科技股份有限公 司章程》等相关规定，本次日常性关联交易预计及确认事项无需提交 公司股东大会审议。 | 关联交易 | 关联人 | 关联交 | 关联交易 | 合同签订 金额或预 | 截至披露日 | 上年发生金 | | --- | --- | --- | --- | --- | --- | --- | | 类别 | | 易内容 | 定价原则 | 计金额 | 已发生金额 ...

一、充分发挥公司综合竞争优势，发展成为全球行业龙头 公司是一家立足中国的综合型医疗护理产品供应商，业务遍及全 球。自成立以来，公司始终以客户需求为导向，致力于为全球医疗行 业、工业、服务业以及个人提供优质的医疗用品和服务。公司总部设 在山东淄博，主营业务涵盖个人防护、康复护理、其他产品三大板块， 主要产品包括一次性手套、轮椅、冷热敷、电极片等多种类型的护理 产品，产品广泛应用于医疗机构、养老护理机构、家庭日用及其他相 关行业。经过多年的发展，公司已成为全球领先的医疗耗材供应商之 一。 证券代码：300677 证券简称：英科医疗 公告编号：2025-053 英科医疗科技股份有限公司 关于"质量回报双提升"行动方案的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 为践行中央政治局会议提出的"要活跃资本市场、提振投资者信 心"及国务院常务会议提出的"要大力提升上市公司质量和投资价值， 要采取更加有力有效措施，着力稳市场、稳信心"的指导思想，英科 医疗科技股份有限公司（以下简称"公司"）于 2024 年 3 月 7 日在 巨潮资讯网（www.cninfo.com. ...

英科医疗科技股份有限公司 关于公司及子公司使用闲置自有资金 证券代码：300677 证券简称：英科医疗 公告编号：2025-048 购买理财产品的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、投资种类：安全性高、流动性好的理财产品。 2、投资金额：最高额度不超过 200 亿元人民币（或等值其他币 种）的闲置自有资金。 3、特别风险提示：尽管公司严格评估、筛选安全性高、低风险 投资品种，但金融市场受宏观经济的影响较大，不排除投资受到市场 波动的影响。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第四届董事会第二次（定期）会议和第四届监事会第二次 （定期）会议，审议通过了《关于公司及子公司使用闲置自有资金购 买理财产品的议案》，同意公司及子公司在不影响公司正常经营和确 保资金安全的情况下，在授权期限内任一时点使用额度不超过 200 亿 元人民币（或等值其他币种）的闲置自有资金购买安全性高、流动性 好的理财产品；该事项不属于关联交易，尚需提交公司 2024 年度股 东大会审议，自经公司 2024 年度股东大 ...